Navigation Links
Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.

LONDON, August 14, 2013 /PRNewswire/ --

The U.S. equity market ended higher on Tuesday, August 13, 2013, after finishing on a mixed note in the previous trading session. The S&P 500 rose 0.28% to close at 1,694.16. The biotechnology companies ended mostly lower, even as the broader market edged higher. The major movers in the sector included BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), PDL BioPharma Inc. (NASDAQ: PDLI), and Amgen Inc. (NASDAQ: AMGN). has released full comprehensive research on BCRX, QCOR, PDLI, and AMGN. These free technical analyses can be downloaded by signing up at:  

Shares in BioCryst Pharmaceuticals Inc. fell sharply on Tuesday, even as the broader market posted gains. The company's shares closed the day 2.31% lower at $5.50 after oscillating between $5.43 and $5.71. A total of 1.32 million shares were traded which is below the daily average volume of 3.54 million. BioCryst Pharmaceuticals Inc.'s shares have gained 203.87% in the last three months, as compared to a gain of 3.70% in the S&P 500 during the same period. Moreover, the company's shares are trading above their 50-day and 200-day moving averages. Download free report on BCRX upon registration at:

Shares in Questcor Pharmaceuticals Inc. surged on Tuesday, tracking gains in the broader market. The company's shares oscillated between $66.25 and $69.33 before finishing the day 4.40% higher at $69.05. A total of 1.93 million shares were traded which is marginally above the daily average volume of 1.92 million. Questcor Pharmaceuticals' shares have gained 40.06% in the last one month and 84.13% in the last three months, outperforming the S&P 500 which has gained 0.83% and 3.70% in the respective periods. Moreover, the stock is currently trading near its 52-week high of $70.55. QCOR technical report can be accessed for free by signing up at:

PDL BioPharma Inc.'s shares fluctuated between $8.34 and $8.45 on Tuesday before ending the day 0.36% lower at $8.41. A total of 1.67 million shares were traded which is below the daily average volume of 1.84 million. The company's shares have gained 3.44% during the last three trading sessions, and 3.70% in the last three months. Despite Tuesday's pullback, the stock is trading near its 52-week high of $8.48, and also above its 50-day and 200-day moving averages. The free report on PDLI can be downloaded by signing up now at:

Amgen Inc.'s stock ended slightly lower on Tuesday, finishing at $107.86, down 0.32% from its previous closing price. The company's shares oscillated between $107.03 and $108.92. A total of 2.68 million shares were traded which is below the daily average volume of 3.22 million. The stock has gained 3.44% in the last one month, outperforming the S&P 500 which has gained 0.83% during the same period. Additionally, the stock is trading above its 50-day and 200-day moving averages. A free report on AMGN can be accessed by registering at:



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquiries, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE AAA Research Reports
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Early Morning Insight: Baxter, CareFusion, Unilife, and Mindray Medical
2. "Good in the Morning" is the Tastiest Summer Single by Mike Brumm of Milwaukee, WI
3. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
4. More than Morning Sickness: Kate Middletons Pregnancy Announcement Draws Attention to Rare Pregnancy Condition Known as Hyperemesis Gravidarum (HG)
5. Brand new Solid Form Co-Crystals and Amorphous Focus Morning at the Pharmaceutical Co-Crystals and Amorphous Material 2012 Summits
6. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
7. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
8. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
9. New Research: Nationwide Report Shows Prescribed Drugs Not Detected in More Than One-Third of Pain Patient Samples
10. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at
11. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
(Date:11/25/2015)... issue of United States patent No. 9,192,509  entitled: " Methods and Apparatus ... AVACEN 100 dry heat therapy medical device and specific methods of use, referred to by the ... - ... ... ...
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
Breaking Medicine Technology:
(Date:11/26/2015)... Cambridge, ON (PRWEB) , ... November 26, 2015 ... ... availability of a real-time eReferral system for diagnostic imaging in the Waterloo region. ... mammography, BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record books ... their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA ... rebuild lives and it’s an honor to have served all of these women.” , ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 , ... ... Thanksgiving through Christmas Eve on several models of traditional and far-infrared saunas. ... . Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only ...
(Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
Breaking Medicine News(10 mins):